- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-DYKDDDDK Tag magnetic beads
- Anti-DYKDDDDK Tag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
Tie-2
Tie-2 Products
- All (11)
- Tie-2 Inhibitors (4)
- Tie-2 Antibodies (4)
- New Tie-2 Products
| Catalog No. | Product Name | Information | Product Use Citations | Product Validations |
|---|---|---|---|---|
| S1361 | MGCD-265 analog | MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2. |
|
|
| S1577 | Tie2 kinase inhibitor 1 | Tie2 kinase inhibitor 1 is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM, 200-fold more potent than p38. |
|
|
| S7799 | Pexmetinib | Pexmetinib is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1. | ||
| S6412 | Altiratinib | Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM. | ||
| F2164New | Angiopoietin 2/ANG2 Rabbit mAb | Angiopoietin 2/ANG2,Angiopoietin 2/Ang-2/ANGPT2,Angiopoietin-2 | ||
| F2487New | Angiopoietin 1 Rabbit mAb | |||
| F1427New | Tie2 Rabbit mAb | CD202b (TIE2),Tie2,Tie2/TEK | ||
| A2725 | Anti-TIE2 / CD202b | Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD. | ||
| A2771 | Zansecimab (Anti-ANGPT2) | Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD. | ||
| A4052New | Faricimab (Anti-Angiopoietin 2 & VEGF-A) | Faricimab is a humanized bispecific antibody that targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), key regulators of vascular leakage and inflammation. It is used to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion, improving retinal vascular stability. M.W 146.41 kDa | ||
| A4064New | Vanucizumab (Anti-Angiopoietin 2 & VEGF) | Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa | ||
| S1361 | MGCD-265 analog | MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2. |
|
|
| S1577 | Tie2 kinase inhibitor 1 | Tie2 kinase inhibitor 1 is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM, 200-fold more potent than p38. |
|
|
| S7799 | Pexmetinib | Pexmetinib is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1. | ||
| S6412 | Altiratinib | Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM. | ||
| A2725 | Anti-TIE2 / CD202b | Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD. | ||
| A2771 | Zansecimab (Anti-ANGPT2) | Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD. | ||
| A4052New | Faricimab (Anti-Angiopoietin 2 & VEGF-A) | Faricimab is a humanized bispecific antibody that targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), key regulators of vascular leakage and inflammation. It is used to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion, improving retinal vascular stability. M.W 146.41 kDa | ||
| A4064New | Vanucizumab (Anti-Angiopoietin 2 & VEGF) | Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa | ||
| F2164New | Angiopoietin 2/ANG2 Rabbit mAb | Angiopoietin 2/ANG2,Angiopoietin 2/Ang-2/ANGPT2,Angiopoietin-2 | ||
| F2487New | Angiopoietin 1 Rabbit mAb | |||
| F1427New | Tie2 Rabbit mAb | CD202b (TIE2),Tie2,Tie2/TEK | ||
| A4052New | Faricimab (Anti-Angiopoietin 2 & VEGF-A) | Faricimab is a humanized bispecific antibody that targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), key regulators of vascular leakage and inflammation. It is used to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion, improving retinal vascular stability. M.W 146.41 kDa | ||
| A4064New | Vanucizumab (Anti-Angiopoietin 2 & VEGF) | Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa |
Choose Selective Tie-2 Inhibitors
Tie-2Signaling Pathway
Tags: Tie-2 signaling | TEK kinase activty | Tie-2 kinase activty | Tie-2 pathway | Tie-2 phosphorylation | Tie2 signaling pathway | Tie-2 inhibitor review
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.